References
- Guimarães HP, Lopes RD, De Barros EGM, et al. Rivaroxaban in patients with atrial fibrillation and a bioprosthetic mitral valve. N Engl J Med. 2020;383(22):2117–2126. doi:https://doi.org/10.1056/NEJMoa2029603.
- Singer DE, Chang Y, Fang MC, et al. The net clinical benefit of warfarin anticoagulation in atrial fibrillation. Ann Intern Med. 2009;151(5):297–305. doi:https://doi.org/10.7326/0003-4819-151-5-200909010-00003.
- Carnicelli Anthony P, Raffaele DC, Halperin Jonathan L, et al. Edoxaban for the prevention of thromboembolism in patients with atrial fibrillation and bioprosthetic valves. Circulation. 2017;135(13):1273–1275. doi:https://doi.org/10.1161/CIRCULATIONAHA.116.026714.
- Durães AR, de Souza Roriz P, de Almeida Nunes B, et al. Dabigatran versus warfarin after bioprosthesis valve replacement for the management of atrial fibrillation postoperatively: DAWA pilot study. Drugs R D. 2016;16(2):149–154. doi:https://doi.org/10.1007/s40268-016-0124-1.
- Guimarães PO, Pokorney SD, Lopes RD, et al. Efficacy and safety of apixaban vs warfarin in patients with atrial fibrillation and prior bioprosthetic valve replacement or valve repair: insights from the ARISTOTLE trial. Clin Cardiol. 2019;42(5):568–571. doi:https://doi.org/10.1002/clc.23178.